Skip to main content
. Author manuscript; available in PMC: 2021 Jul 28.
Published in final edited form as: Eur J Haematol. 2016 Dec 1;98(3):263–268. doi: 10.1111/ejh.12826

Table 2.

Type of induction regimens, [N (%)]

IMiD-based regimen 15 (29)
PI-based regimen 15 (29)
IMiD + PI-based regimen 16 (31)
Conventional chemotherapy 2 (4)
No induction treatment 3 (6)
Maintenance therapy after auto-HCT 16 (31)

IMiD, immunomodulatory drugs (lenalidomide or thalidomide); PI, proteasome inhibitors; auto-HCT, autologous hematopoietic stem cell transplant; conventional, alkylating agent or steroid based therapy.